Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aquestive Therapeutics, Inc.AQST · Entity 5276 | Chief People Officer | September 09, 2026 | September 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aquestive Therapeutics, Inc.
Report date September 09, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 284,024 |
Reported balance
After 2026-09-09 transaction · row 1
1 source rowRow 1 · 2026-09-09 · Other · Acquired 2,293 · Balance 284,024 F1: Represents the exercise for cash of a Common Stock Purchase Warrant issued to the Reporting Person on June 8, 2022 pursuant to a Securities Purchase Agreement dated June 6, 2022. The warrant became exercisable on December 8, 2022, expires on June 8, 2027, and has an exercise price of $0.96 per share. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.96 · Expires 2027-06-08 | Direct | 0 |
Reported balance
After 2026-09-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-09 · Other · Disposed 2,293 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the exercise for cash of a Common Stock Purchase Warrant issued to the Reporting Person on June 8, 2022 pursuant to a Securities Purchase Agreement dated June 6, 2022. The warrant became exercisable on December 8, 2022, expires on June 8, 2027, and has an exercise price of $0.96 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2026 Filed Sep 10, 2026 13:21 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | OtherWarrant (Right to Buy) · Derivative | 2,293 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001214659-26-011541 · marketforms-73978.xml · derivative · entry 2 Boyd Peter E. · CIK 0001739816 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,293 shares Expires 2027-06-08 Read SEC document |
| September 09, 2026 Filed Sep 10, 2026 13:21 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | OtherCommon Stock | 2,293 | $0.96 | $2,201.28 |
DisclosureSEC source: 0001214659-26-011541 · marketforms-73978.xml · nonDerivative · entry 1 Boyd Peter E. · CIK 0001739816 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 284,024 F1 · shares: Represents the exercise for cash of a Common Stock Purchase Warrant issued to the Reporting Person on June 8, 2022 pursuant to a Securities Purchase Agreement dated June 6, 2022. The warrant became exercisable on December 8, 2022, expires on June 8, 2027, and has an exercise price of $0.96 per share. F1 · price: Represents the exercise for cash of a Common Stock Purchase Warrant issued to the Reporting Person on June 8, 2022 pursuant to a Securities Purchase Agreement dated June 6, 2022. The warrant became exercisable on December 8, 2022, expires on June 8, 2027, and has an exercise price of $0.96 per share. Read SEC document |
| May 05, 2026 Filed May 7, 2026 21:34 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 56,778 | $4.18 | $237,332.04 |
DisclosureSEC source: 0001214659-26-005751 · marketforms-73068.xml · nonDerivative · entry 1 Boyd Peter E. · CIK 0001739816 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,731 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Performance Stock Units ("PSUs") previously granted to the Reporting Person. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 16:52 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | SaleCommon Stock | 29,814 | $4.17 | $124,413.82 |
DisclosureSEC source: 0001214659-26-003147 · marketforms-72463.xml · nonDerivative · entry 2 Boyd Peter E. · CIK 0001739816 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,509 F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $4.17 to $4.33. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 16:52 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 42,500 | $4.29 Strike: $4.29 | $182,325.00 |
DisclosureSEC source: 0001214659-26-003147 · marketforms-72463.xml · derivative · entry 3 Boyd Peter E. · CIK 0001739816 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires 2036-03-09 F4 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 16:52 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-26-003147 · marketforms-72463.xml · nonDerivative · entry 1 Boyd Peter E. · CIK 0001739816 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 368,323 F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 18:06 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-25-017652 · marketforms-71415.xml · nonDerivative · entry 1 Boyd Peter E. · CIK 0001739816 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 288,323 F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 18:00 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | SaleCommon Stock | 10,000 | $7.00 | $70,000.00 |
DisclosureSEC source: 0001214659-25-015046 · marketforms-71047.xml · nonDerivative · entry 1 Boyd Peter E. · CIK 0001739816 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 268,323 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4. Read SEC document |
| September 26, 2025 Filed Sep 29, 2025 20:26 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | SaleCommon Stock | 10,000 | $6.30 | $63,000.00 |
DisclosureSEC source: 0001214659-25-014287 · marketforms-70873.xml · nonDerivative · entry 1 Boyd Peter E. · CIK 0001739816 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 278,323 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4. Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 21:13 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | SaleCommon Stock | 15,000 | $5.30 | $79,500.00 |
DisclosureSEC source: 0001214659-25-013485 · marketforms-70566.xml · nonDerivative · entry 1 Boyd Peter E. · CIK 0001739816 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 288,323 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4. Read SEC document |
| March 09, 2025 Filed Mar 11, 2025 21:47 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 7,681 | $2.65 | $20,354.65 |
DisclosureSEC source: 0001214659-25-004222 · marketforms-68504.xml · nonDerivative · entry 3 Boyd Peter E. · CIK 0001739816 · See Remark 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 303,323 F2 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 21:47 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001214659-25-004222 · marketforms-68504.xml · derivative · entry 4 Boyd Peter E. · CIK 0001739816 · See Remark 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-03-07 F3 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 21:47 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 6,624 | $2.65 | $17,553.60 |
DisclosureSEC source: 0001214659-25-004222 · marketforms-68504.xml · nonDerivative · entry 2 Boyd Peter E. · CIK 0001739816 · See Remark 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 311,004 F2 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 21:47 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-25-004222 · marketforms-68504.xml · nonDerivative · entry 1 Boyd Peter E. · CIK 0001739816 · See Remark 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 317,628 F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 07, 2025 Filed Apr 13, 2026 19:54 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantPerformance Stock Units · Derivative | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-26-004596 · marketforms-72925.xml · derivative · entry 1 Boyd Peter E. · CIK 0001739816 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2028-03-07 F1 · security: This Form 4 was filed late due to an inadvertent administrative oversight. F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Company's common stock. The PSUs measure performance from March 7, 2025 (Grant Date) through March 7, 2028 and, if earned, vest 100% on March 7, 2028. "Performance Price" means (i) the 30-day average Nasdaq closing price ending on the last day of the period from the Grant Date through the day before the second anniversary (First Pricing Period) and (ii) the highest 30-day average Nasdaq closing price during the period from the second through the third anniversary (Second Pricing Period). F2 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the Company's common stock. The PSUs measure performance from March 7, 2025 (Grant Date) through March 7, 2028 and, if earned, vest 100% on March 7, 2028. "Performance Price" means (i) the 30-day average Nasdaq closing price ending on the last day of the period from the Grant Date through the day before the second anniversary (First Pricing Period) and (ii) the highest 30-day average Nasdaq closing price during the period from the second through the third anniversary (Second Pricing Period). Read SEC document |
| March 09, 2024 Filed Mar 12, 2024 17:47 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 8,370 | $4.88 | $40,845.60 |
DisclosureSEC source: 0001214659-24-004394 · marketforms-65146.xml · nonDerivative · entry 1 Boyd Peter E. · CIK 0001739816 · See Remark 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,628 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 14:35 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 43,125 | $0.00 Strike: $5.68 | $0.00 |
DisclosureSEC source: 0001214659-24-004303 · marketforms-64689.xml · derivative · entry 2 Boyd Peter E. · CIK 0001739816 · See Remark 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,125 Underlying: Common Stock · 43,125 shares Expires 2034-03-07 F3 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 14:35 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 86,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-24-004303 · marketforms-64689.xml · nonDerivative · entry 1 Boyd Peter E. · CIK 0001739816 · See Remark 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,998 F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. F2 · balance_after: The original Form 4, filed on 3/9/23, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the inclusion of shares for 59,532 shares owned when in fact 59,748 shares of the Issuer's common stock were owned. As a result of this administrative error, the number of shares beneficially owned by the reporting person following the corrected transaction reflects an increase in the number of shares reported as beneficially owned by the reporting person by 216 shares. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:30 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantPerformance Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-010925 · marketforms-61885.xml · derivative · entry 1 Boyd Peter E. · CIK 0001739816 · See Remark 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2026-05-05 F1 · derivative.exercise_price: Each performance-based stock unit ("PSU") represents a contingent right to receive one share of the Company's Common Stock. The PSUs have a Performance Period beginning on the Grant Date and ending on May 5, 2026 and, to the extent earned, will vest 100% on that date, subject to the grantee's continued employment or other service with the Company from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the Performance Period is subject to increase or decrease from 50% to up to 150%, based on the achievement of pre-established Performance Price metrics. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period. F1 · derivative.exercise_date: Each performance-based stock unit ("PSU") represents a contingent right to receive one share of the Company's Common Stock. The PSUs have a Performance Period beginning on the Grant Date and ending on May 5, 2026 and, to the extent earned, will vest 100% on that date, subject to the grantee's continued employment or other service with the Company from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the Performance Period is subject to increase or decrease from 50% to up to 150%, based on the achievement of pre-established Performance Price metrics. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period. Read SEC document |
| May 05, 2023 Filed May 5, 2023 20:00 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantPerformance Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-006555 · marketforms-61236.xml · derivative · entry 1 Boyd Peter E. · CIK 0001739816 · See Remark 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2026-05-05 F1 · derivative.exercise_price: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of Aquestive ("Company") common stock. The PSUs have a three-year Performance Period, and, to the extent earned, will vest 100% on the third anniversary of the grant date, subject to the grantee's continued employment or other service with the Company or any Subsidiary from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the three-year Performance Period is subject to increase or decrease based on the results of the Performance Price. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period. F1 · derivative.exercise_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of Aquestive ("Company") common stock. The PSUs have a three-year Performance Period, and, to the extent earned, will vest 100% on the third anniversary of the grant date, subject to the grantee's continued employment or other service with the Company or any Subsidiary from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the three-year Performance Period is subject to increase or decrease based on the results of the Performance Price. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period. Read SEC document |
| March 09, 2023 Filed Mar 9, 2023 20:07 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-003695 · marketforms-59523.xml · nonDerivative · entry 1 Boyd Peter E. · CIK 0001739816 · See Remark 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,532 F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| November 04, 2022 Filed Nov 8, 2022 15:23 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001214659-22-013282 · marketforms-57370.xml · derivative · entry 1 Boyd Peter E. · CIK 0001739816 · SVP-Bus. Process & Info. Tech. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-11-04 F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| June 14, 2022 Filed Jun 15, 2022 14:24 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | PurchaseCommon Stock | 5,000 | $0.81 | $4,050.00 |
DisclosureSEC source: 0001628280-22-017186 · wf-form4_165530302948520.xml · nonDerivative · entry 1 Boyd Peter E. · CIK 0001739816 · SVP-Bus. Process & Info. Tech. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,532 F1 · price: This transaction was executed in multiple transactions at the price of $0.81. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and price at which the transaction was effected. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 21:26 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | PurchaseWarrant (Right to Buy) · Derivative | 2,293 | $0.13 Strike: $0.96 | $298.09 |
DisclosureSEC source: 0001628280-22-016872 · wf-form4_165489636547699.xml · derivative · entry 2 Boyd Peter E. · CIK 0001739816 · SVP-Bus. Process & Info. Tech. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,293 Underlying: Common Stock · 2,293 shares Expires 2027-06-08 F1 · price: Each share of common stock sold to the Reporting Person was sold together with one warrant to purchase one share of common stock at a price per share of $1.09 per share and warrant, of which the price per share of common stock was deemed to be $0.96 and the price per warrant was deemed to be $0.13 Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 21:26 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | PurchaseCommon Stock | 2,293 | $0.96 | $2,201.28 |
DisclosureSEC source: 0001628280-22-016872 · wf-form4_165489636547699.xml · nonDerivative · entry 1 Boyd Peter E. · CIK 0001739816 · SVP-Bus. Process & Info. Tech. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,532 F1 · price: Each share of common stock sold to the Reporting Person was sold together with one warrant to purchase one share of common stock at a price per share of $1.09 per share and warrant, of which the price per share of common stock was deemed to be $0.96 and the price per warrant was deemed to be $0.13 Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 15:24 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001214659-22-003895 · marketforms-55761.xml · derivative · entry 1 Boyd Peter E. · CIK 0001739816 · SVP-Bus. Process & Info. Tech. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2032-03-10 F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 21:10 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001214659-21-003146 · marketforms-51877.xml · derivative · entry 1 Boyd Peter E. · CIK 0001739816 · SVP-Bus. Process & Info. Tech. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2031-03-11 F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 20:45 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,700 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0001214659-20-002746 · marketforms-48349.xml · derivative · entry 2 Boyd Peter E. · CIK 0001739816 · SVP-Bus. Process & Info. Tech. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,700 Underlying: Common Stock · 50,700 shares Expires 2030-03-16 F1 · derivative.exercise_date: The units subject to the Award shall vest 25% 1st year, 25% 2nd year and 50% 3rd year on the commencement anniversaries. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 20:45 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | PurchaseCommon Stock | 2,000 | $1.50 | $3,000.00 |
DisclosureSEC source: 0001214659-20-002746 · marketforms-48349.xml · nonDerivative · entry 1 Boyd Peter E. · CIK 0001739816 · SVP-Bus. Process & Info. Tech. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,239 Read SEC document |
| August 12, 2019 Filed Aug 13, 2019 20:30 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | PurchaseCommon Stock | 600 | $3.81 | $2,286.00 |
DisclosureSEC source: 0001214659-19-005182 · marketforms-45478.xml · nonDerivative · entry 1 Boyd Peter E. · CIK 0001739816 · SVP-Bus. Process & Info. Tech. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,239 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:47 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $8.05 | $0.00 |
DisclosureSEC source: 0001214659-19-001751 · marketforms-44352.xml · derivative · entry 1 Boyd Peter E. · CIK 0001739816 · SVP-Operations/Value Delivery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-02-28 F1 · derivative.exercise_date: The units subject to the Award shall vest 25% 1st year, 25% 2nd year and 50% 3rd year on the commencement anniversaries. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 18:35 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | PurchaseCommon Stock | 200 | $9.98 | $1,996.00 |
DisclosureSEC source: 0001140361-18-043649 · form4.xml · nonDerivative · entry 1 Boyd Peter E. · CIK 0001739816 · SVP-Operations/Value Delivery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,639 Read SEC document |
| July 24, 2018 Filed Jul 27, 2018 01:14 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 36,223 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001140361-18-033746 · form4.xml · derivative · entry 1 Boyd Peter E. · CIK 0001739816 · SVP-Operations/Value Delivery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,223 Underlying: Common Stock · 36,223 shares Expires 2028-07-24 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 25% of the underlying shares vest on the first anniversary of the grant date, 25% of the underlying shares vest on the second anniversary of the grant date and the remaining 50% of the underlying shares vest on the third anniversary of the grant date, subject in each case to Mr. Boyd's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.